{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T22:35:26Z","timestamp":1792362926943,"version":"4.4.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Amino Acids"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Parkinson\u2019s Disease (PD) is a progressive neurodegenerative disorder characterised by the loss of dopaminergic neurons, leading to both motor and non-motor symptoms. Oxidative stress is a significant contributor to the pathophysiology of PD, and glutathione (GSH) depletion contributes to neuronal damage. N-acetylcysteine (NAC), a bioavailable cysteine donor, can support endogenous GSH synthesis and may also exert antioxidant effects independent of GSH replenishment. NAC and GSH are proposed neuroprotective interventions due to their antioxidant properties. This systematic review evaluated the effects of NAC and GSH on oxidative stress and PD symptoms, comparing them with healthy controls or a placebo. A systematic search was conducted in Cochrane Library, PubMed, Web of Science, Ovid (Embase and MEDLINE), Scopus, and ProQuest for studies published between January 2003 and December 2024, including randomised controlled trials (RCTs) and non-randomised studies. Two reviewers assessed the study quality and extracted data. The primary outcome was the change in motor and non-motor symptoms as measured by the Unified Parkinson\u2019s Disease Rating Scale (UPDRS) and were interpreted using minimal clinically important difference (MCID) thresholds. Secondary outcomes included biochemical redox markers such as blood GSH, cerebrospinal fluid (CSF) GSH, GSSG, and GSH\/GSSG ratio and imaging-based functional outcomes, particularly DAT binding assessed by DaTscan SPECT. The GSH\/GSSG ratio reflects redox status (reduced vs. oxidised glutathione), CSF outcomes primarily reported NAC concentrations, and brain GSH was quantified using magnetic resonance spectroscopy (MRS). Exclusion criteria included studies on conditions other than PD, those that did not use NAC or GSH as the primary intervention, and those without a comparator group. Nine studies, conducted between 2009 and 2019, met the inclusion criteria and involved 196 participants. NAC improved both motor and non-motor symptoms and significantly increased GSH\/GSSG ratios, GSH levels in the CSF, and DAT binding. In contrast, intranasal GSH showed only modest increases in brain levels without significant improvements in symptoms or oxidative stress markers. The studies had limitations, including small sample sizes, short intervention durations, and inconsistencies in dosage and administration routes. These factors constrain the strength of the conclusions, and evidence for both NAC and GSH remains preliminary. Furthermore, while NAC shows promise as a neuroprotective intervention, findings for GSH are inconclusive. More large-scale, long-term randomised controlled trials are needed to validate these results and explore NAC and GSH\u2019s long-term therapeutic potential in managing PD.<\/jats:p>","DOI":"10.1007\/s00726-026-03513-5","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T13:53:17Z","timestamp":1774360397000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The role of N-acetylcysteine and glutathione in the management of Parkinson\u2019s disease: a systematic review of oxidative biomarkers and clinical outcomes"],"prefix":"10.1007","volume":"58","author":[{"given":"Imran","family":"Mohammed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasimin","family":"Nankya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U. Teng","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Kan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alya Masoud","family":"Abdelhafid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0607-6909","authenticated-orcid":false,"given":"Gladys O.","family":"Latunde-Dada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"3513_CR1","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3389\/fneur.2019.00218","volume":"10","author":"N Ball","year":"2019","unstructured":"Ball N, Teo W-P, Chandra S, Chapman J (2019) Parkinson\u2019s disease and the environment. Front Neurol 10:218. https:\/\/doi.org\/10.3389\/fneur.2019.00218","journal-title":"Front Neurol"},{"issue":"2","key":"3513_CR2","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/brb3.208","volume":"4","author":"R Bavarsad Shahripour","year":"2014","unstructured":"Bavarsad Shahripour R, Harrigan MR, Alexandrov AV (2014) N-acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities. Brain Behav 4(2):108\u2013122","journal-title":"Brain Behav"},{"key":"3513_CR4","doi-asserted-by":"publisher","first-page":"105799","DOI":"10.1016\/j.parkreldis.2023.105799","volume":"115","author":"CKBDE Uti","year":"2023","unstructured":"Bhusal CK, Uti DE, Mukherjee D, Alqahtani T, Alqahtani S, Bhattacharya A, Akash S (2023) Unveiling Nature\u2019s potential: Promising natural compounds in Parkinson\u2019s disease management. Parkinsonism Relat Disord 115:105799\u2013105799. https:\/\/doi.org\/10.1016\/j.parkreldis.2023.105799","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"3513_CR3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/jcph.1008","volume":"58","author":"LD Coles","year":"2018","unstructured":"Coles LD, Tuite PJ, \u00d6z G, Mishra UR, Kartha RV, Sullivan KM, Cloyd JC, Terpstra M (2018) Repeated-dose oral N-acetylcysteine in Parkinson disease: pharmacokinetics and effect on brain glutathione and oxidative stress. J Clin Pharmacol 58(2):158\u2013167. https:\/\/doi.org\/10.1002\/jcph.1008","journal-title":"J Clin Pharmacol"},{"key":"3513_CR5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.arr.2017.12.007","volume":"42","author":"H Deng","year":"2018","unstructured":"Deng H, Wang P, Jankovic J (2018) The genetics of Parkinson disease. Ageing Res Rev 42:72\u201385. https:\/\/doi.org\/10.1016\/j.arr.2017.12.007","journal-title":"Ageing Res Rev"},{"issue":"4","key":"3513_CR6","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3233\/jpd-130230","volume":"3","author":"V Dias","year":"2013","unstructured":"Dias V, Junn E, Mouradian MM (2013) The role of oxidative stress in Parkinson\u2019s disease. J Parkinsons Dis 3(4):461\u2013491. https:\/\/doi.org\/10.3233\/jpd-130230","journal-title":"J Parkinsons Dis"},{"issue":"2","key":"3513_CR7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.5152\/npa.2016.12758","volume":"54","author":"E Gokcal","year":"2017","unstructured":"Gokcal E, Gur VE, Selvitop R, Babacan Yildiz G, Asil T (2017) Motor and non-motor symptoms in Parkinson\u2019s disease: effects on quality of life. Noro Psikiyatr Ars 54(2):143\u2013148. https:\/\/doi.org\/10.5152\/npa.2016.12758","journal-title":"Noro Psikiyatr Ars"},{"issue":"3","key":"3513_CR8","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/ejn.14094","volume":"49","author":"JC Greenland","year":"2019","unstructured":"Greenland JC, Williams-Gray CH, Barker RA (2019) The clinical heterogeneity of Parkinson\u2019s disease and its therapeutic implications. Eur J Neurosci 49(3):328\u2013338","journal-title":"Eur J Neurosci"},{"key":"3513_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2202-9-s3-s5","author":"LR Hanson","year":"2008","unstructured":"Hanson LR, Frey WH (2008) Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci. https:\/\/doi.org\/10.1186\/1471-2202-9-s3-s5","journal-title":"BMC Neurosci"},{"issue":"7","key":"3513_CR10","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1002\/mds.22401","volume":"24","author":"RA Hauser","year":"2009","unstructured":"Hauser RA, Lyons KE, McClain T, Carter S, Perlmutter D (2009) Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson\u2019s disease. Mov Disord 24(7):979\u2013983. https:\/\/doi.org\/10.1002\/mds.22401","journal-title":"Mov Disord"},{"key":"3513_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/1765220","volume":"2021","author":"RM Hendricks","year":"2021","unstructured":"Hendricks RM, Khasawneh MT (2021) An investigation into the use and meaning of Parkinson\u2019s disease clinical scale scores. Parkinsons Dis 2021:1\u20137. https:\/\/doi.org\/10.1155\/2021\/1765220","journal-title":"Parkinsons Dis"},{"issue":"4","key":"3513_CR12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/wnf.0b013e31829ae713","volume":"36","author":"MJ Holmay","year":"2013","unstructured":"Holmay MJ, Terpstra M, Coles LD, Mishra U, Ahlskog M, \u00d6z G, Cloyd JC, Tuite PJ (2013) N-acetylcysteine boosts brain and blood glutathione in Gaucher and Parkinson diseases. Clin Neuropharmacol 36(4):103\u2013106. https:\/\/doi.org\/10.1097\/wnf.0b013e31829ae713","journal-title":"Clin Neuropharmacol"},{"issue":"5","key":"3513_CR13","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.parkreldis.2015.02.020","volume":"21","author":"M Katz","year":"2015","unstructured":"Katz M, Won SJ, Park Y, Orr A, Jones DP, Swanson RA, Glass GA (2015) Cerebrospinal fluid concentrations of N-acetylcysteine after oral administration in Parkinson\u2019s disease. Parkinsonism Relat Disord 21(5):500\u2013503. https:\/\/doi.org\/10.1016\/j.parkreldis.2015.02.020","journal-title":"Parkinsonism Relat Disord"},{"key":"3513_CR14","unstructured":"Kouli A, Torsney KM, Kuan W-L (2018) Parkinson\u2019s disease: etiology, neuropathology, and pathogenesis. In: Stoker TB, Greenland JC (eds) PubMed, Codon Publications. https:\/\/pubmed.ncbi.nlm.nih.gov\/30702842\/"},{"issue":"9680","key":"3513_CR15","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1016\/s0140-6736(09)60492-x","volume":"373","author":"AJ Lees","year":"2009","unstructured":"Lees AJ, Hardy J, Revesz T (2009) Parkinson\u2019s disease. Lancet 373(9680):2055\u20132066. https:\/\/doi.org\/10.1016\/s0140-6736(09)60492-x","journal-title":"Lancet"},{"issue":"12","key":"3513_CR18","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1002\/mds.26351","volume":"30","author":"LK Mischley","year":"2015","unstructured":"Mischley LK, Leverenz JB, Lau RC, Polissar NL, Neradilek MB, Samii A, Standish LJ (2015) A randomized, double-blind phase I\/IIa study of intranasal glutathione in Parkinson\u2019s disease. Mov Disord 30(12):1696\u20131701. https:\/\/doi.org\/10.1002\/mds.26351","journal-title":"Mov Disord"},{"key":"3513_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/npjparkd.2016.2","author":"LK Mischley","year":"2016","unstructured":"Mischley LK, Conley KE et al (2016) Central nervous system uptake of intranasal glutathione in Parkinson\u2019s disease. NPJ Parkinsons Dis. https:\/\/doi.org\/10.1038\/npjparkd.2016.2","journal-title":"NPJ Parkinsons Dis"},{"issue":"2","key":"3513_CR17","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3233\/JPD-161040","volume":"7","author":"LK Mischley","year":"2017","unstructured":"Mischley LK, Lau RC, Shankland EG, Wilbur TK, Padowski JM (2017) Phase IIb study of intranasal glutathione in Parkinson\u2019s disease. J Parkinsons Dis 7(2):289\u2013299. https:\/\/doi.org\/10.3233\/JPD-161040","journal-title":"J Parkinsons Dis"},{"issue":"5","key":"3513_CR19","doi-asserted-by":"publisher","first-page":"e26479","DOI":"10.1016\/j.heliyon.2024.e26479","volume":"10","author":"B Mishra","year":"2024","unstructured":"Mishra B, Sudheer P, Rajan R, Agarwal A, Srivastava P, Nilima N, Vishnu VY (2024) Bridging the gap between statistical significance and clinical relevance: A systematic review of minimum clinically important difference (MCID) thresholds of scales reported in movement disorders research. Heliyon 10(5):e26479\u2013e26479. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e26479","journal-title":"Heliyon"},{"issue":"6","key":"3513_CR21","doi-asserted-by":"publisher","first-page":"e0157602","DOI":"10.1371\/journal.pone.0157602","volume":"11","author":"DA Monti","year":"2016","unstructured":"Monti DA, Zabrecky et al (2016) N-acetyl cysteine may support dopamine neurons in Parkinson\u2019s disease: preliminary clinical and cell line data. PLoS ONE 11(6):e0157602. https:\/\/doi.org\/10.1371\/journal.pone.0157602","journal-title":"PLoS ONE"},{"key":"3513_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1548","author":"DA Monti","year":"2019","unstructured":"Monti DA, Zabrecky G, Kremens D et al (2019) N-acetyl cysteine is associated with dopaminergic improvement in Parkinson\u2019s disease. Clin Pharmacol Ther. https:\/\/doi.org\/10.1002\/cpt.1548","journal-title":"Clin Pharmacol Ther"},{"issue":"06","key":"3513_CR22","doi-asserted-by":"publisher","first-page":"001","DOI":"10.1055\/s-0043-1777775","volume":"82","author":"RP Munhoz","year":"2024","unstructured":"Munhoz RP, Tumas V, Jos\u00e9 L, Pedroso, Silveira-Moriyama L (2024) The clinical diagnosis of Parkinson\u2019s disease. Arq Neuropsiquiatr 82(06):001\u2013010. https:\/\/doi.org\/10.1055\/s-0043-1777775","journal-title":"Arq Neuropsiquiatr"},{"key":"3513_CR23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"3513_CR24","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.neubiorev.2015.04.015","volume":"55","author":"J Slattery","year":"2015","unstructured":"Slattery J, Kumar N, Delhey L, Berk M, Dean O, Spielholz C, Frye R (2015) Clinical trials of N-acetylcysteine in psychiatry and neurology: a systematic review. Neurosci Biobehav Rev 55:294\u2013321","journal-title":"Neurosci Biobehav Rev"},{"key":"3513_CR25","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"3513_CR28","doi-asserted-by":"publisher","unstructured":"Tardiolo G. Bramanti P, Mazzon E (2018) Overview on the effects of N-acetylcysteine in neurodegenerative diseases. Molecules 23(12). https:\/\/doi.org\/10.3390\/molecules23123305","DOI":"10.3390\/molecules23123305"},{"issue":"6","key":"3513_CR26","doi-asserted-by":"publisher","first-page":"967","DOI":"10.3390\/antiox10060967","volume":"10","author":"MCDS Ten\u00f3rio","year":"2021","unstructured":"Ten\u00f3rio MCDS, Graciliano NG, Moura FA, Oliveira ACMD, Goulart MOF (2021) N-acetylcysteine (NAC): impacts on human health. Antioxidants 10(6):967","journal-title":"Antioxidants"},{"key":"3513_CR27","unstructured":"Wells G, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, Tugwell P (2021) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Www.ohri.ca. https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"}],"container-title":["Amino Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00726-026-03513-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00726-026-03513-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00726-026-03513-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T10:42:31Z","timestamp":1775299351000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00726-026-03513-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3513"],"URL":"https:\/\/doi.org\/10.1007\/s00726-026-03513-5","relation":{},"ISSN":["1438-2199"],"issn-type":[{"value":"1438-2199","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Human Ethics and Consent to Participate declarations: not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"26"}}